UNIVERSITY OF NORTH CAROLINA HOSPITALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1989-01-01

Employees: -

Market Cap: -

Website: http://www.unc.edu/interactive-tour/unc-hospitals/

Clinical Trials

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Phase 2

Active, not recruiting

Conditions: Lip
Digestive Organs--Diseases
Larynx
Oral Cancer

Interventions: Drug: Durvalumab
Radiation: Intensity Modulated Radiotherapy Treatments

First Posted Date: 2018-05-18

Last Posted Date: 2024-07-16

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT03529422

Locations: 🇺🇸
University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
Medical University of South Carolina - Hollings Cancer Center, Charleston, South Carolina, United States

Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2018-04-05

Last Posted Date: 2021-01-13

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 34

Registration Number: NCT03488862

Locations: 🇺🇸
UNC Lineberger, Chapel Hill, North Carolina, United States

Efficacy of a Couple-Focused mHealth Symptom Self-management Program

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: usual care plus NCI website
Behavioral: Prostate Cancer Education and Resources for Couples (PERC)

First Posted Date: 2018-04-05

Last Posted Date: 2024-10-03

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 560

Registration Number: NCT03489057

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colon Neoplasms
Neoplasms, Colonic
Cancer of the Colon
Colon Cancer
Colonic Cancer

Interventions: Drug: Cetuximab
Drug: Palbociclib

First Posted Date: 2018-02-26

Last Posted Date: 2024-08-07

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT03446157

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Phase 2

Active, not recruiting

Conditions: Colon Cancer

Interventions: Drug: Panitumumab
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-02-22

Last Posted Date: 2024-05-14

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 56

Registration Number: NCT03442569

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 2 locations

Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain

Phase 2

Terminated

Conditions: Breast Cancer
Lymphoma
Pain

Interventions: Drug: Placebo
Drug: Pregabalin

First Posted Date: 2018-01-23

Last Posted Date: 2018-06-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT03407430

Locations: 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States

Enhancing Source Credibility in Tobacco Regulatory Communications

Not Applicable

Completed

Conditions: Cigarette Smoking Behavior

Interventions: Behavioral: Constituent message with FDA and quitline
Behavioral: Constituent message without FDA and quitline
Behavioral: Littering message (Control)

First Posted Date: 2017-11-13

Last Posted Date: 2020-11-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 845

Registration Number: NCT03339206

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: TAD

First Posted Date: 2017-09-13

Last Posted Date: 2023-01-04

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 100

Registration Number: NCT03281720

Locations: 🇺🇸
UNC- Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Phase 2

Active, not recruiting

Conditions: Adult T-Cell Leukemia/Lymphoma
Lymphatic Diseases
Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: CHEP

First Posted Date: 2017-08-28

Last Posted Date: 2024-10-29

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT03264131

Locations: 🇺🇸
South Broward/Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 1 locations

High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Completed

Conditions: Hematopoietic Stem Cell Transplantation
Delirium
Thiamine Deficiency

Interventions: Drug: Normal saline
Drug: Thiamine

First Posted Date: 2017-08-28

Last Posted Date: 2021-10-19

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 66

Registration Number: NCT03263442

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy